[go: up one dir, main page]

AR008875A1 - Derivados de 2-cianoiminoimidazol inhibidores de pde iv, procedimiento para su preparacion, composicion que los contienen, procedimiento para preparar dicha composicion y uso de dichos compuestos para la preparacion de medicamentos. - Google Patents

Derivados de 2-cianoiminoimidazol inhibidores de pde iv, procedimiento para su preparacion, composicion que los contienen, procedimiento para preparar dicha composicion y uso de dichos compuestos para la preparacion de medicamentos.

Info

Publication number
AR008875A1
AR008875A1 ARP970104528A ARP970104528A AR008875A1 AR 008875 A1 AR008875 A1 AR 008875A1 AR P970104528 A ARP970104528 A AR P970104528A AR P970104528 A ARP970104528 A AR P970104528A AR 008875 A1 AR008875 A1 AR 008875A1
Authority
AR
Argentina
Prior art keywords
preparation
hydrogen
procedure
derivatives
6alkyl
Prior art date
Application number
ARP970104528A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR008875A1 publication Critical patent/AR008875A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/48Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de 2-cianoiminoimidazol que tienen la formula (I) las formas N- oxido, las sales de adicion farmacéuticamente aceptables, y las formasestereoquímicamente isomeras de los mismos, en donde: R1 y R2 son cada uno independientementehidro geno, C1-6 alquilo, difluorometilo, trifluorometilo,C3-6 cicloalquilo, un heterociclo de 5, 6, o 7 miembros saturado que contiene uno o dos heteroátomos seleccionados de oxígeno, azufre, o nitrogeno, indanilo,6,7-dihidro-5H-ciclopentapiridinilo, bi cilo [2.2.1]-2-heptenilo, bicilo [2.2.1] heptanilo, C1-6 alquilsulfonilo, arilsulfonilo, o C1-10 alquilo sustituido;R3 es hidrogeno, halo o C1-6 alquiloxi; R4 es hidrogeno, halo, C1-6 alquilo, trifluorometilo, C3-6cicloalquilo, carboxilo, C1-4 al quiloxicarbonilo, C3-6cicloalquilaminocarbonilo, arilo, Het1, o C1-6 alquilo sustituido, o R4 es O-R7 o -NH-R8; R5 es hidrogeno, halo, hidroxi, C1-6 alquilo, o C1-6 alquiloxi;R6 es un hidrogeno o C1-4 alquilo, oR4 y R6 o R4 y R5 tomados juntos pueden formar un radical bivalente; -A-B- es CR10=CR11- o CHR10-CHR11-; L eshidrogeno, C1-6 alquilo, C1-6 alquilcarbonilo; C1-6 alquiloxicarbonilo, C1-6 alquilo sustituido, C3-6 alquenilo, C3-6 alquenilosustituido,piperidinilo, piperidini lo sustituido, C1-6 alquilsulfonilo o arilsulfonilo, que tienen actividad inhbidora de PDE IV y citoquina; procesos para lapreparacion de compuestos de formula (I), composiciones farmacéuticas de los mismos,proceso para la preparacion de dicha s composiciones y uso de dichosderivados en la fabricacion de medicamentos.
ARP970104528A 1996-10-02 1997-10-01 Derivados de 2-cianoiminoimidazol inhibidores de pde iv, procedimiento para su preparacion, composicion que los contienen, procedimiento para preparar dicha composicion y uso de dichos compuestos para la preparacion de medicamentos. AR008875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02

Publications (1)

Publication Number Publication Date
AR008875A1 true AR008875A1 (es) 2000-02-23

Family

ID=8224456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104528A AR008875A1 (es) 1996-10-02 1997-10-01 Derivados de 2-cianoiminoimidazol inhibidores de pde iv, procedimiento para su preparacion, composicion que los contienen, procedimiento para preparar dicha composicion y uso de dichos compuestos para la preparacion de medicamentos.

Country Status (30)

Country Link
US (1) US6051718A (es)
EP (1) EP0934280B1 (es)
JP (1) JP3068208B2 (es)
KR (1) KR100520002B1 (es)
CN (1) CN1106387C (es)
AR (1) AR008875A1 (es)
AT (1) ATE236884T1 (es)
AU (1) AU719561B2 (es)
BG (1) BG64278B1 (es)
BR (1) BR9712256B1 (es)
CA (1) CA2267322C (es)
CY (1) CY2380B1 (es)
CZ (1) CZ297474B6 (es)
DE (1) DE69720757T2 (es)
DK (1) DK0934280T3 (es)
EE (1) EE03825B1 (es)
ES (1) ES2196308T3 (es)
HU (1) HU225158B1 (es)
IL (2) IL129298A0 (es)
MY (1) MY116980A (es)
NO (1) NO312960B1 (es)
NZ (1) NZ334971A (es)
PL (1) PL194673B1 (es)
PT (1) PT934280E (es)
RU (1) RU2180902C2 (es)
SI (1) SI0934280T1 (es)
SK (1) SK285878B6 (es)
TR (1) TR199900732T2 (es)
UA (1) UA62939C2 (es)
WO (1) WO1998014432A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138745A0 (en) * 1998-04-01 2001-10-31 Janssen Pharmaceutica Nv Pde iv inhibiting pyridine derivatives
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
ES2462995T3 (es) 2001-04-19 2014-05-27 Eisai R&D Management Co., Ltd. Derivados de 2-iminoisoindolinona como antagonistas del receptor de la trombina
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
CN100358514C (zh) * 2001-07-11 2008-01-02 日研化学株式会社 过敏性眼疾病治疗剂
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
DK1463493T3 (da) 2001-12-14 2008-02-04 Serono Lab Fremgangsmåder til at inducere æglösning ved anvendelse af en ikke polypeptid-cAMP-niveaumodulator
CA2515715C (en) * 2003-02-19 2012-05-08 Eisai Co., Ltd. Methods for producing cyclic benzamidine derivatives
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2861580B1 (en) * 2012-06-07 2018-04-25 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
PL307265A1 (en) * 1992-07-28 1995-05-15 Rhone Poulenc Rorer Ltd Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom
CA2400368A1 (en) * 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DE69430747T2 (de) * 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling Verbindungen als pde iv und tnf inhibitoren
EP0714397A1 (en) * 1993-08-19 1996-06-05 Smithkline Beecham Corporation Phenethylamine compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
WO1996000218A1 (en) * 1994-06-24 1996-01-04 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
KR20000029964A (ko) 2000-05-25
TR199900732T2 (xx) 1999-08-23
UA62939C2 (uk) 2004-01-15
BR9712256B1 (pt) 2011-04-19
PT934280E (pt) 2003-08-29
IL129298A0 (en) 2000-02-17
EP0934280B1 (en) 2003-04-09
JP3068208B2 (ja) 2000-07-24
SI0934280T1 (en) 2003-12-31
EE9900112A (et) 1999-10-15
HUP9904063A3 (en) 2000-11-28
HUP9904063A2 (hu) 2000-09-28
ATE236884T1 (de) 2003-04-15
HK1020344A1 (en) 2000-04-14
EP0934280A1 (en) 1999-08-11
MY116980A (en) 2004-04-30
CA2267322C (en) 2007-11-06
AU4779297A (en) 1998-04-24
BR9712256A (pt) 1999-08-24
PL194673B1 (pl) 2007-06-29
SK285878B6 (sk) 2007-10-04
CN1232456A (zh) 1999-10-20
PL332573A1 (en) 1999-09-27
US6051718A (en) 2000-04-18
NO312960B1 (no) 2002-07-22
WO1998014432A1 (en) 1998-04-09
HU225158B1 (en) 2006-07-28
KR100520002B1 (ko) 2005-10-13
DK0934280T3 (da) 2003-07-21
CY2380B1 (en) 2004-06-04
CA2267322A1 (en) 1998-04-09
DE69720757T2 (de) 2004-03-04
JP2000503678A (ja) 2000-03-28
SK34499A3 (en) 2000-04-10
EE03825B1 (et) 2002-08-15
DE69720757D1 (de) 2003-05-15
CN1106387C (zh) 2003-04-23
RU2180902C2 (ru) 2002-03-27
AU719561B2 (en) 2000-05-11
BG64278B1 (bg) 2004-08-31
NO991560D0 (no) 1999-03-30
CZ102899A3 (cs) 1999-07-14
BG103220A (en) 1999-11-30
NO991560L (no) 1999-06-02
CZ297474B6 (cs) 2006-12-13
IL129298A (en) 2006-04-10
ES2196308T3 (es) 2003-12-16
NZ334971A (en) 2000-09-29

Similar Documents

Publication Publication Date Title
AR008875A1 (es) Derivados de 2-cianoiminoimidazol inhibidores de pde iv, procedimiento para su preparacion, composicion que los contienen, procedimiento para preparar dicha composicion y uso de dichos compuestos para la preparacion de medicamentos.
ES2055860T3 (es) Derivados 2-aminopirimidinona.
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
NO2007017I1 (no) 3-Ä2-Ä4-(6-fluor -1,2-benzoksazol-3 -yl)-1-piperidinylÜ etylÜ-6,7,8,9-tetrahydro-9-hydroksy-2-metyl-4H-pyridolÄ1,2-aÜpyrimidin-4-on (palperidone)
AR005731A1 (es) Tiofenopirimidinas, un procedimiento para su preparacion, el uso de las mismas como medicamento, una composicion que las contiene, un procedimientopara preparar dicha composicion, compuestos intermediarios para su exclusivo uso en dicho procedimiento y un procedimiento para su preparacion.
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
DK0648778T3 (da) Nye 11-benzaldoximestradien-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
AR002732A1 (es) Derivados de 1,3-dihidro-1-(fenilalquilo)-2-h-imidazol-2-ona, uso de los derivados para preparar un medicamento, composiciones farmacéuticas que contienen dichos derivados, un procedimiento para su preparación, y un procedimiento para preparar dichos derivados
DK0495982T3 (da) Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel
NO883229D0 (no) Nye benzimidazolderivater, fremgangsmaate for deres fremstilling og farmasoeytisk preparat inneholdende slike derivater.
FI884375A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(1-alkyyli-3-hydroksi-4-piperidinyyli)bentsamidien valmistamiseksi
NO942952D0 (no) 11-benzaldoksin-17 ater, fremgangsmåte for deres fremstilling samt legemiddel inneholdende slike
MY113446A (en) 1,3-dihydro-1-(phenylalkenyl)-2h-imidazol-2-one derivatives
ES2045083T3 (es) Un procedimiento para preparar un compuesto quimico.
PT861250E (pt) Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them
CA2326045A1 (en) Pde iv inhibiting pyridine derivatives
MY117936A (en) 1,3-dihydro-2h-imidazol-2-one derivatives
NO303011B1 (no) 4-amino-N-(4-metyl-4-piperidinyl)-2-metoksybenzamider
DK0437120T3 (da) Pyridonderivater, deres fremstilling og anvendelse som lægemidler samt farmaceutiske præparater med indhold heraf og hidtil ukendte mellemprodukter
EE9900582A (et) 5-asendatud-1,2,4-tiadiasolüülderivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon, vaheühend ja selle valmistamismeetod
ES2076201T3 (es) Derivados de 3-piperidinil-indazol antihipertensivos.

Legal Events

Date Code Title Description
FG Grant, registration